Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE-4: Orforglipron vs Insulin Glargine in T2DM and Obesity
NCT05803421Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of orforglipron in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) at 104 weeks. Started Apr 2023; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05803421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803421.